PI
TXMD icon

PEAK6 Investments’s TherapeuticsMD TXMD Stock Holding History

PEAK6 Investments’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-50,000
Closed -$280K – 4986
2022
Q4 		$280K Sell
50,000
-8,500
-15% -$50K ﹤0.01% 3027
2022
Q3 		$388K Buy
+58,500
New +$474K ﹤0.01% 3119

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
CC
Clearline Capital New York $1.68B AUM 53.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $243M AUM 9.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
SSP
Sixth Street Partners Dallas, Texas $579M AUM 2.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return

PEAK6 Investments's TXMD Position: Q1 2023 in Review

PEAK6 Investments sold out of TherapeuticsMD (TXMD) in Q1 2023, closing a stake of 40,127 shares — an estimated $224K sold.

PEAK6 Investments first reported a position in TXMD in Q3 2022 and held it in 2 quarters. The position peaked at $224K in Q4 2022. 41 funds tracked by Wall St. Rank hold TXMD as of Q1 2023.

  • PEAK6 Investments reported no remaining TherapeuticsMD position as of Q1 2023 after selling out during the quarter.
  • PEAK6 Investments sold 40,127 TherapeuticsMD shares in Q1 2023, an estimated $224K.
  • PEAK6 Investments first reported a position in TherapeuticsMD in Q3 2022 and held it in 2 quarters.
  • PEAK6 Investments's TherapeuticsMD position peaked at $224K in Q4 2022.
  • 41 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2023.

Based on PEAK6 Investments's 13F filing for Q1 2023, filed 12 May 2023.